BioNTech's Bifurcated Picture: ASCO Data Impress, but Restructuring and Founder Exit Loom Large
03.06.2026 - 12:12:26 | boerse-global.de
BioNTech emerged from the ASCO annual meeting in Chicago with two clinical lifts that drew a rare upgrade from UBS, yet the stock remains under water — down 7% year to date and 25% below its 52-week high of €101.90. The disconnect between pipeline progress and market sentiment is stark, and it deepened this week as the company unveiled a sweeping production overhaul that will see it quit three German sites and its Singapore plant by early 2027.
UBS moved BioNTech to Buy from Neutral and raised its price target to $135 from $117, citing growing confidence in the late-stage oncology pipeline. At the cancer conference, the biotech presented Phase-2 data for gotistobart in platinum-resistant ovarian cancer, showing durable overall survival in patients with few remaining options. Alongside that, results from the ROSETTA Lung-02 study for pumitamig — a bispecific antibody — recorded confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous non-small cell lung cancer. BMO Capital Markets called the data a validation of the bispecific approach and a sign that BioNTech is now a credible contender against oncology heavyweights like Merck.
Not all analysts are convinced. Bernstein initiated with a Market Perform rating and a $96 target, signaling limited upside until clinical wins translate into regulatory approvals and revenue. The divergence highlights the fundamental question hanging over BioNTech: can scientific promise be turned into commercial reality before the cash cushion runs thin?
Should investors sell immediately? Or is it worth buying BioNTech?
The company ended the first quarter of 2026 with €16.8 billion in cash and securities, but the burn rate remains high. Revenue slid to €118.1 million from €182.8 million a year earlier, while the net loss widened to €531.9 million — a diluted loss per share of €2.10 compared with €1.73 in the prior-year period. Management is sticking to its full-year guidance of €2.0 billion to €2.3 billion in revenue, and plans to spend €2.2 billion to €2.5 billion on R&D. A €500 million annual cost-saving program, targeting full run-rate by 2029, is meant to redirect resources into the oncology pipeline.
That restructuring is already reshaping the company’s physical footprint. BioNTech is evaluating sales of production sites by the end of the third quarter, with full or partial divestitures possible. In Germany, it will exit Idar-Oberstein, Marburg and Tübingen by the end of 2027. Marburg alone houses eight production suites capable of churning out mRNA for up to three billion vaccine doses a year. In Singapore, operations will wind down in the first quarter of 2027. CFO Ramón Zapata confirmed that after the end of 2026, all COVID-19 vaccine supply will be handled by Pfizer through its existing capacity. A separate $1 billion share buyback program is also underway.
The pipeline, meanwhile, remains the central narrative. By year-end, BioNTech expects to deliver six more late-stage datasets, including Phase-3 results for BNT113 and interim data from the pivotal PRESERVE-003 study of gotistobart. Across the board, more than 25 Phase-2 and Phase-3 studies are running, 13 of them registration-enabling. The company’s stated target is to obtain approvals in ten cancer indications by 2030.
Adding to the transition, founders Ugur Sahin and Özlem Türeci plan to step down from their operational roles by the end of 2026. The incoming management team inherits a clear mandate: convert the clinical data into approved products and prove that BioNTech can thrive beyond its COVID-era success. For now, the share price — hovering around €76.65 — suggests the market is still waiting for that proof.
Ad
BioNTech Stock: New Analysis - 3 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
